| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Bank of America Securities downgrades European drugmaker Galapagos NV (NASDAQ:GLPG) to underperform, citing few catalysts in the near term.
Galapagos’ enterprise value has been consistently low, ranging between $1.5 billion and $2 billion, and the analysts don’t anticipate any immediate or medium-term solutions to this.
Additionally, the company’s main programs are entering crowded markets where differentiation is unclear, and there is a lack of significant catalysts to drive growth.
Galapagos’ primary cancer pipeline requires 3 to 4 years to reach the market, accompanied by significant cash depletion and uncertain standing in fiercely competitive markets.
Moreover, Galapagos’ emphasis on acquiring early-stage assets increases the risk for investors, potentially leading to a decline in the stock price.
BofA Securities’ downgrade to “Underperform” from “Neutral” is due to concerns that the stock may continue to be a value trap and underperform compared to its peers. The analyst lowered the price target from $41 to $31.
Galapagos is currently conducting three early-stage trials to assess its autologous cell therapy (CAR-T) treatments for hematologic cancers.
The unique selling points of Galapagos’ CAR-Ts lie in their potential differentiators:
Thus, BofA sees a smaller commercial opportunity for Galapagos’ CAR-T candidates and lower revenue forecasts by 15-25% in out-years (2028E+).
Price Action: GLPG shares are up 0.16% at $32.25 on the last check Monday.
Image: Shutterstock
